Jump to Navigation


The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to address HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians.


Recent News
Apr 24, 2017

Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following shareholder update authored by its Chairman and CEO, Jim Joyce. Dear Shareholders, I first want to express my appreciation for...

Apr 4, 2017

Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, disclosed today that an interview conducted with Company CEO Jim...

View all News Releases

Monday, April 3, 2017

Episode 17-13 Health Tec, the NFL, Major League Baseball and Neuroscience http://www.technation.com/

Thursday, March 30, 2017
3:00pm CDT

View All Events

print email

Back to Top

Site 'Subpage' Navigation:

Investor Relations

Investor Contact

Aethlon Medical, Inc.

Back to Top